Infliximab dependency is related to decreased surgical rates in adult Crohn's disease patients
- 1 October 2010
- journal article
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 22 (10) , 1196-1203
Abstract
Infliximab dependency in children with Crohn's disease (CD) has recently been described and found to be associated with a decreased surgery rate. To assess infliximab dependency of adult CD patients, evaluate the impact on surgery, and search for possible clinical and genetic predictors. Two hundred and forty-five CD patients treated with infliximab were included from Danish and Czech Crohn Colitis Database (1999-2006). Infliximab response was assessed as immediate outcome, 1 month after infliximab start: complete, partial, and no response. Three months outcome, after last intended infusion: prolonged response (maintenance of complete/partial response), infliximab dependency (relapse requiring repeated infusions to regain complete/partial response or need of infliximab >12 months to sustain response). Forty-seven percent obtained prolonged response, 29% were infliximab dependent and 24% nonresponders. The cumulative probability of surgery 40 months after infliximab start was 20% in prolonged responders, 23% in infliximab-dependent patients and 76% in nonresponders (P<0.001). The cumulative probability of surgery at 40 months in patients on maintenance versus on demand regime was 33 and 31%, respectively (P=0.63). No relevant clinical or genetic predictors were identified. The infliximab dependency response seems to be equivalent to the prolonged response in adult CD patients when comparing surgery rates.Keywords
This publication has 38 references indexed in Scilit:
- Clinical outcome of newly diagnosed Crohn’s disease: a comparative, retrospective study before and after infliximab availabilityAlimentary Pharmacology & Therapeutics, 2009
- Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infectionsAlimentary Pharmacology & Therapeutics, 2009
- Infliximab dependency in children with Crohn’s diseaseAlimentary Pharmacology & Therapeutics, 2009
- Disseminated tuberculosis in a Crohn's disease patient on anti-TNF therapy despite chemoprophylaxisGut, 2008
- Mucosal Healing in Inflammatory Bowel Disease: Results From a Norwegian Population-Based CohortGastroenterology, 2007
- Induction and Maintenance Infliximab Therapy for the Treatment of Moderate-to-Severe Crohn’s Disease in ChildrenGastroenterology, 2007
- Infliximab therapy in Crohn's disease: a pragmatic approach?Alimentary Pharmacology & Therapeutics, 2006
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialThe Lancet, 2002
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001
- Invasive Pulmonary Aspergillosis Associated with Infliximab TherapyNew England Journal of Medicine, 2001